{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:30:25Z","timestamp":1785432625873,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.contraception.2019.09.009","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T19:41:00Z","timestamp":1571859660000},"page":"46-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Label comprehension of a combined mifepristone and misoprostol product for medical abortion: A pilot study in South Africa"],"prefix":"10.1016","volume":"101","author":[{"given":"Nathalie","family":"Kapp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jewelle","family":"Methazia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Eckersberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tshegofatso","family":"Bessenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.contraception.2019.09.009_b0005","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2471\/BLT.10.084046","article-title":"Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review","volume":"89","author":"Ngo","year":"2011","journal-title":"Bull World Health Organ"},{"issue":"2","key":"10.1016\/j.contraception.2019.09.009_b0010","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-0412.2011.01285.x","article-title":"Regional differences in surgical intervention following medical termination of pregnancy provided by telemedicine","volume":"91","author":"Gomperts","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"9","key":"10.1016\/j.contraception.2019.09.009_b0015","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1471-0528.2008.01787.x","article-title":"Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services","volume":"115","author":"Gomperts","year":"2008","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.contraception.2019.09.009_b0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.contraception.2013.11.005","article-title":"Provision of medical abortion using telemedicine in Brazil","volume":"89","author":"Gomperts","year":"2014","journal-title":"Contraception."},{"key":"10.1016\/j.contraception.2019.09.009_b0025","article-title":"Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland","volume":"357","author":"Aiken","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.contraception.2019.09.009_b0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.contraception.2017.08.002","article-title":"Feasibility of assessing the safety and effectiveness of menstrual regulation medications purchased from pharmacies in Bangladesh: a prospective cohort study","volume":"97","author":"Footman","year":"2018","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.contraception.2019.09.009_b0035","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.contraception.2017.09.007","article-title":"Developing a forward-looking agenda and methodologies for research of self-use of medical abortion","volume":"97","author":"Kapp","year":"2018","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.contraception.2019.09.009_b0040","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.contraception.2015.07.001","article-title":"Introducing medication abortion into public sector facilities in KwaZulu-Natal, South Africa: an operations research study","volume":"92","author":"Blanchard","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2019.09.009_b0045","series-title":"Distribution and Marketing of drugs in South Africa","year":"2018"},{"key":"10.1016\/j.contraception.2019.09.009_b0050","unstructured":"Republic of South Africa. Government Gazette. Department of Health; 2017. Contract No.: 41064."},{"issue":"1","key":"10.1016\/j.contraception.2019.09.009_b0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1590\/S0100-72032010000100004","article-title":"Evaluation of the teratogenic risks in gestations exposed to misoprostol","volume":"32","author":"Opaleye","year":"2010","journal-title":"Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia."},{"issue":"3","key":"10.1016\/j.contraception.2019.09.009_b0060","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijgo.2016.02.018","article-title":"Prospective study of home use of mifepristone and misoprostol for medical abortion up to 10weeks of pregnancy in Kazakhstan","volume":"134","author":"Platais","year":"2016","journal-title":"Int J Gynaecol Obstetrics"},{"issue":"11","key":"10.1016\/j.contraception.2019.09.009_b0065","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/1471-0528.14646","article-title":"A research agenda for moving early medical pregnancy termination over the counter","volume":"124","author":"Kapp","year":"2017","journal-title":"BJOG"},{"issue":"4","key":"10.1016\/j.contraception.2019.09.009_b0070","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.contraception.2017.09.016","article-title":"Exploring the feasibility of obtaining mifepristone and misoprostol from the internet","volume":"97","author":"Murtagh","year":"2018","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.contraception.2019.09.009_b0075","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.contraception.2017.09.006","article-title":"Efficacy of medical abortion prior to 6 gestational weeks: a systematic review","volume":"97","author":"Kapp","year":"2018","journal-title":"Contraception."},{"issue":"5","key":"10.1016\/j.contraception.2019.09.009_b0080","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0009-9236(03)00239-X","article-title":"Label development and the label comprehension study for over-the-counter drugs","volume":"74","author":"Brass","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2019.09.009_b0085","series-title":"Clinical Trials to Support Prescription to Over-the-Counter Switches","author":"Brass","year":"2014"},{"key":"10.1016\/j.contraception.2019.09.009_b0090","unstructured":"FDA. Guidance for Industry--Label Comprehension Studies of Nonprescription Drug Products: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2010 [Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM143834.pdf."},{"issue":"1","key":"10.1016\/j.contraception.2019.09.009_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4102\/hsag.v15i1.468","article-title":"Adaptation of the Rapid Estimate of Adult Literacy in Medicine Revised (REALM-R) to the South African Context: Part 1","volume":"15","author":"Wasserman","year":"2010","journal-title":"Health SA Gesondheid."},{"issue":"2","key":"10.1016\/j.contraception.2019.09.009_b0100","first-page":"342","article-title":"Comprehension of a prototype over-the-counter label for an emergency contraceptive pill product","volume":"100","author":"Raymond","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.contraception.2019.09.009_b0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.contraception.2008.09.004","article-title":"Comprehension of a prototype emergency contraception package label by female adolescents","volume":"79","author":"Raymond","year":"2009","journal-title":"Contraception."},{"issue":"23","key":"10.1016\/j.contraception.2019.09.009_b0110","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1056\/NEJMe1604462","article-title":"A New Label for Mifepristone","volume":"374","author":"Greene","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.contraception.2019.09.009_b0115","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.contraception.2015.04.008","article-title":"Early medical abortion without prior ultrasound","volume":"92","author":"Raymond","year":"2015","journal-title":"Contraception."},{"issue":"1","key":"10.1016\/j.contraception.2019.09.009_b0120","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4102\/phcfm.v8i1.1094","article-title":"Contraceptive practices among women seeking termination of pregnancy in one public hospital in Eastern Cape, South Africa","volume":"8","author":"Oluwole","year":"2016","journal-title":"Afr J Prim Health Care Fam Med."},{"issue":"4","key":"10.1016\/j.contraception.2019.09.009_b0125","article-title":"The effectiveness of nonprescription drug labels in the united states: insights from recent research and opportunities for the future","volume":"6","author":"Catlin","year":"2018","journal-title":"Pharmacy (Basel)"},{"issue":"8","key":"10.1016\/j.contraception.2019.09.009_b0130","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1525-1497.2006.00529.x","article-title":"Low literacy impairs comprehension of prescription drug warning labels","volume":"21","author":"Davis","year":"2006","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.contraception.2019.09.009_b0135","unstructured":"Commission E. Guideline on the readability of the labelling and package leaflet of medicinal products for human use. Brussels; 2009. Contract No.: 12.1.2009."},{"key":"10.1016\/j.contraception.2019.09.009_b0140","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4054\/DemRes.2015.33.35","article-title":"Educational attainment and adult literacy A descriptive account of 31 Sub-Saharan Africa countries","volume":"33","author":"Smith-Greenaway","year":"2015","journal-title":"Demographic Res"},{"key":"10.1016\/j.contraception.2019.09.009_b0145","series-title":"Demographic and Health Survey","year":"2016"},{"issue":"4","key":"10.1016\/j.contraception.2019.09.009_b0150","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1363\/3117205","article-title":"Pharmacists' knowledge and perceptions of emergency contraceptive pills in Soweto and the Johannesburg Central Business District, South Africa","volume":"31","author":"Blanchard","year":"2005","journal-title":"Int Fam Plan Perspect."},{"issue":"4","key":"10.1016\/j.contraception.2019.09.009_b0155","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/13625180802255701","article-title":"Emergency contraception in South Africa: a literature review","volume":"13","author":"Maharaj","year":"2008","journal-title":"Eur J Contracept Reprod Health Care."},{"key":"10.1016\/j.contraception.2019.09.009_b0160","series-title":"National Contraception Policy guidelines within a reproductive health framework- Republic of South Africa","author":"Department of Health","year":"2003"},{"issue":"2","key":"10.1016\/j.contraception.2019.09.009_b0165","doi-asserted-by":"crossref","DOI":"10.1177\/2055102917720331","article-title":"Does the Drug Facts Label for nonprescription drugs meet its design objectives? A new procedure for assessing label effectiveness","volume":"4","author":"Ryan","year":"2017","journal-title":"Health Psychol Open"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782419304330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782419304330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:14:50Z","timestamp":1757880890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782419304330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0010782419304330"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2019.09.009","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Label comprehension of a combined mifepristone and misoprostol product for medical abortion: A pilot study in South Africa","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2019.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}